A private equity fund in China mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.
The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; biotech products in Biosimilar, Vaccines, blood product, etc.; and Traditional Chinese Medicine (TCM). The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.
The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers companies with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has a strong network in China and can offer assistance in distribution and registration. For therapeutics, the firm prefers companies who have completed Phase 1 and Phase 2a trials and can show some safety and efficacy data.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment